Diatide AcuTect
Executive Summary
Company receives "approvable" letter Feb. 20 for its Tc 99 apcitide product for imaging of acute venothrombosis in lower extremities. Diatide expects to launch AcuTect in the third quarter of 1998 with a sales force of about 10 reps marketing to radiopharmacies. Diatide's marketing partner Nycomed will market it to physicians, hospitals and preferred provider organizations. AcuTect was recommended for approval Feb. 9 ("The Pink Sheet" Feb. 16, p. 5)..